Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Did you mean trifadium citrate dihydrate and dextrose and fructose?
Displaying drugs 451 - 475 of 14357 in total

Plecanatide

Plecanatide is a drug approved in January 2017 by the FDA for the treatment of chronic idiopathic constipation (CIC). It should not be used in children less than six years of age, and should be avoided in patients six years to 18 years of age
Approved
Investigational
Matched Description: … It should not be used in children less than six years of age, and should be avoided in patients six years …
Matched Categories: … Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Tenecteplase

Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at amino acids...
Approved
Matched Description: … 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at amino acids 296- ... It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine …
Matched Categories: … Enzymes and Coenzymes ... Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …

Elotuzumab

Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family member 7, a cell surface glycoprotein. Elotuzumab...
Approved
Matched Description: … Food and Drug Administration. ... a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and ... complementary determining regions (CDR) of the mouse antibody, MuLuc63, grafted onto human IgG1 heavy and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Reviparin

Reviparin is a low molecular weight heparin which seems to have a better safety profile than unfractionated heparin. It is prepared from porcine intestinal mucosa by nitrous acid depolymerization. Reviparin has a molecular weight of 3.9 kDa. It was developed by Abbott laboratories and in 2009, reviparin presented an orphan...
Approved
Investigational
Matched Description: … [A32021] It was developed by Abbott laboratories and in 2009, reviparin presented an orphan drug designation …
Matched Categories: … Heparin and similars ... Blood and Blood Forming Organs …

Talimogene laherparepvec

Talimogene laherparepvec is an oncolytic treatment used in local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with recurrent melanoma. It is a genetically administered herpes simplex virus 1 (HSV-1) that expresses human cytokine granulocyte-macrophage colony stimulating factor (GM-CSF) with antitumor and immune-stimulating activities. It specifically replicates within...
Approved
Experimental
Investigational
Matched Description: … It specifically replicates within tumor cells and causes lysis. ... laherparepvec is an oncolytic treatment used in local treatment of unresectable cutaneous, subcutaneous, and ... that expresses human cytokine granulocyte-macrophage colony stimulating factor (GM-CSF) with antitumor and …
Matched Categories: … Antineoplastic cell and gene therapy ... Antineoplastic and Immunomodulating Agents …

Tinzaparin

Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for high affinity binding...
Approved
Matched Description: … It is an anticoagulant and considered an antithrombotic. ... It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. ... Tinzaparin is composed of molecules with and without a special site for high affinity binding to antithrombin …
Matched Categories: … Heparin and similars ... Blood and Blood Forming Organs …

Glutathione disulfide

A GLUTATHIONE dimer formed by a disulfide bond between the cysteine sulfhydryl side chains during the course of being oxidized.
Approved
Experimental
Investigational
Matched Categories: … Amino Acids, Peptides, and Proteins …

Luspatercept

Luspatercept is a recombinant fusion protein comprised of a modified extracellular domain of activin receptor type IIB fused to the FC domain of human IgG1.[A187829,L42455] It was first approved for use in the United States in November 2019 under the brand name Reblozyl® for the treatment of anemia in patients...
Approved
Investigational
Matched Description: … the treatment of conditions in which late-stage erythropoiesis is defective, such as beta thalassemia and ... erythropoiesis, in contrast to typical erythropoiesis-stimulating agents (ESAs), such as [darbepoetin alfa] and …
Matched Categories: … Enzymes and Coenzymes ... Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins ... Intracellular Signaling Peptides and Proteins …

Calcium acetate

The chemical compound calcium acetate is the calcium salt of acetic acid. It has been commonly referred to as the acetate of lime. The anhydrous form is very hygroscopic, therefore the monohydrate is the common form.
Approved
Investigational
Matched Categories: … Alimentary Tract and Metabolism ... ascorbic acid (vit C) and calcium ... calcium acetate and magnesium carbonate ... Drugs for Treatment of Hyperkalemia and Hyperphosphatemia …

Peginterferon beta-1a

Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of...
Approved
Matched Description: … , disrupting communication between the brain and other parts of the body. ... Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system ... fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Intercellular Signaling Peptides and Proteins …

Thrombin

Also known as coagulation factor II, thrombin is a serine protease that plays a physiological role in regulating hemostasis and maintaining blood coagulation. Once converted from prothrombin, thrombin converts fibrinogen to fibrin, which, in combination with platelets from the blood, forms a clot. Medical thrombin is a protein substance produced...
Approved
Investigational
Matched Description: … coagulation factor II, thrombin is a serine protease that plays a physiological role in regulating hemostasis and ... Patients who are know or suspected to have antibodies to bovine thrombin and/or bovine factor V should ... These antibodies may subsequently cross-react with endogenous human factor V and lead to its deficiency …
Matched Categories: … Enzymes and Coenzymes ... Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …

Mogamulizumab

Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous; these cancers typically...
Approved
Investigational
Matched Description: … antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and ... Approval in Japan was granted on April 30 2012 by the Japanese Ministry of Health, Labour and Welfare ... Food and Drug Administration (FDA) approved mogamulizumab injection (also known as _Poteligeo_) for intravenous …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Etelcalcetide

Etelcalcetide is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis. Etelcalcetide was approved (trade name Parsabiv) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis in February, 2017.
Approved
Investigational
Matched Categories: … Sex Hormones and Insulins ... Amino Acids, Peptides, and Proteins …

Sulesomab

Market product is Tc99m-labeled murine antibody fragment for nuclear imaging of activated granulocytes.
Approved
Matched Categories: … Amino Acids, Peptides, and Proteins ... Inflammation and Infection Detection …

Interferon alfa-n1

Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes.
Approved
Investigational
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Intercellular Signaling Peptides and Proteins …

Quinethazone

Quinethazone, marketed as Hydromox, is a thiazide diuretic indicated for hypertension. Patients may experience adverse reactions such as dizziness, dry mouth, nausea, and hypokalemia.
Approved
Matched Description: … Patients may experience adverse reactions such as dizziness, dry mouth, nausea, and hypokalemia. …
Matched Categories: … quinethazone and potassium ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …

Ertugliflozin

Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018.
Approved
Investigational
Matched Categories: … Alimentary Tract and Metabolism ... metformin and ertugliflozin ... sitagliptin and ertugliflozin …

Cenegermin

Cenegermin is a human beta-nerve growth factor (beta-ngf)-(1-118)- peptide (non-covalent dimer) produced in escherichia coli. It received European Union Approval in July 2017 for the treatment of moderate to severe neurotrophic keratitis. Cenegermin received approval from the US FDA a year later in August of 2018. Neurotrophic keratitis is a...
Approved
Investigational
Matched Description: … causing progressive damage to the top layer of the cornea, including corneal thinning, ulceration, and ... L4563] While the prevalence of neurotrophic keratitis is low, the impact of this serious condition and ... Cenegermin also received Orphan Drug designation, which provides incentives to assist and encourage the …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Intercellular Signaling Peptides and Proteins …

Rozanolixizumab

Rozanolixizumab is a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P) targeting the immunoglobulin G (IgG). Rozonolixizumab itself is an IgG4P, an inactive isotype, to reduce the likelihood of unwanted chain exchange. It is investigated for use in autoimmune and alloimmune diseases with pathologic IgG, particularly generalized myasthenia...
Approved
Investigational
Matched Description: … by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) in November 2020. ... Rozanolixizumab-noli is available under the brand name RYSTIGGO and was developed by UCB. ... [A260177] It is investigated for use in autoimmune and alloimmune diseases with pathologic IgG, particularly …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Human interferon beta

Human interferon beta is a polypeptide used in the management of relapsing forms of Multiple Sclerosis (MS), and was initially approved by the FDA in 1992. Multiple Sclerosis is a devastating neurodegenerative disease that is usually progressive and significantly debilitating with a profound impact on the quality of life. Interferon...
Approved
Investigational
Matched Description: … interferon beta is a polypeptide used in the management of relapsing forms of Multiple Sclerosis (MS), and ... [L12081] Multiple Sclerosis is a devastating neurodegenerative disease that is usually progressive and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Intercellular Signaling Peptides and Proteins …

Crizanlizumab

Crizanlizumab is a humanized IgG2 monoclonal antibody used to reduce the frequency of vaso-occlusive crises in patients with sickle cell disease. Sickle cell disease is a genetically inherited condition prevalent in the Middle East, Africa, and certain parts of India. The genetic mutation associated with this disease leads to the...
Approved
Investigational
Matched Description: … It was developed by Novartis and was granted FDA approval on November 15, 2019. ... L10097] Sickle cell disease is a genetically inherited condition prevalent in the Middle East, Africa, and ... Sickle cell disease can lead to excruciating pain, stroke, infection, and various other complications …
Matched Categories: … Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …

Sincalide

Sincalide is a medication given by injection to assist in the diagnosis of gallbladder and pancreas disorders. It is identified as the 8-amino acid C-terminal segment of cholecystokinin and is also known as CCK-8. Naturally occurring cholecystokinin is a gastrointestinal peptide hormone normally essential for stimulating protein and fat digestion...
Approved
Matched Description: … Furthermore, sincalide stimulates the pancreatic secretion of bicarbonate and enzymes. ... It is identified as the 8-amino acid C-terminal segment of cholecystokinin and is also known as _CCK- ... Sincalide is a medication given by injection to assist in the diagnosis of gallbladder and pancreas disorders …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Cefmetazole

A semisynthetic cephamycin antibiotic with a broad spectrum of activity against both gram-positive and gram-negative microorganisms. It has a high rate of efficacy in many types of infection and to date no severe side effects have been noted.
Approved
Investigational
Matched Description: … A semisynthetic cephamycin antibiotic with a broad spectrum of activity against both gram-positive and ... It has a high rate of efficacy in many types of infection and to date no severe side effects have been …

Argatroban

Argatroban is a direct, selective thrombin inhibitor. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary intervention. Argatroban is a non-heparin anticoagulant shown to both normalize platelet count in patients...
Approved
Investigational
Matched Description: … Parental anticoagulants must be stopped and a baseline activated partial thromboplastin time must be ... Argatroban is a non-heparin anticoagulant shown to both normalize platelet count in patients with HIT and ... bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and …
Matched Categories: … Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …

Flucloxacillin

Antibiotic analog of cloxacillin.
Approved
Investigational
Displaying drugs 451 - 475 of 14357 in total